|05/07/18||Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent|
|COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 patent”), written reasons for which were received on March 22, 2018. The notice was filed to the Technical Board of Appeal (the “TBA”) of the EPO.
“With the notice of appeal filed, we officially initiate t... |
|04/30/18||Forward Pharma Reports Full-Year 2017 Financial and Operational Results|
|COPENHAGEN, Denmark, April 30, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the year ended December 31, 2017. Net income for the year ended December 31, 2017 was $917.1 million, or $2.30 per diluted share, versus net loss of $(33.3) million, or $(0.06) per share for the year ended December 31, 2016. As of December 31, 2017, the Company had $109.6 million in cash and cash equivalents, with no debt outstanding... |
|02/07/18||Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference|
|COPENHAGEN, Denmark, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will give a corporate update at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY. Dr. Svendsen will present on Thursday, February 15, 2018 at 10:30 AM ET and host one-on-one meetings.
Investors and other interested parties may access a live audio webcast of our conference presentati... |
|01/29/18||Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent|
|Forward Pharma Expects to Appeal the Decision Upon Review
COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’355 patent”) following the oral hearing in the Opposition Proceedings.
The EPO Opposition Division revoked the ’355 patent after considering third-party oppositions from several opponents. The Opposition Division will is... |